<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AMPA <z:chebi fb="68" ids="48706">antagonists</z:chebi> have been shown to be remarkably neuroprotective in models of global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but the data in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> remain controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We, therefore, studied the dose-response characteristics and the time window of efficacy of the AMPA <z:chebi fb="68" ids="48706">antagonist</z:chebi> NBQX in a rat model of permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>NBQX 40, 60 or 100 mg/kg i.v., substantially reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="3" pm="."><plain>Neuroprotection was maintained when the initiation of drug administration was withheld for 15, 45 or 90 min after permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, NBQX did not induce heat shock protein in cingulate cortex, as do some <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, the compound is a potent neuroprotectant in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and has an unusually long time window of effectiveness </plain></SENT>
</text></document>